**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 62532

**Manuscript Type:** CORRECTION

**Corrigendum to “Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases”**

Sang LX. Corrigendum to “Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases”

Li-Xuan Sang

**Li-Xuan Sang,** Department of Geriatrics, the First Affiliated Hospital, China Medical University, Shenyang 110001, Liaoning Province, China

**Author contributions:** Sang LX solely contributed to this paper.

**Corresponding author: Li-Xuan Sang, PhD, Associate Professor,** Department of Geriatrics, the First Affiliated Hospital, China Medical University, No. 155, Nanjing North Street, Heping District, Shenyang 110001, Liaoning Province, China. sanglixuan2008@163.com

**Received:** January 11, 2021

**Revised:** May 7, 2021

**Accepted:** May 24, 2021

**Published online:** July 16, 2021

**Abstract**

Correction to: Cheng FS, Pan D, Chang B, Jiang M, Sang LX. Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases. *World J Clin Cases* 2020; 8: 1361-1384. We are the team of Min Jiang and Li-Xuan Sang from the First Affiliated Hospital, China Medical University. Now we solemnly declare that the studies mentioned in this article[1] evaluated the probiotic formulation known as VSL#3 before January 31, 2016. The probiotic formulation is now commonly referred to as De Simone Formulation. In addition, the product currently known as VSL#3 is not the same as De Simone Formulation. De Simone Formulation is now available as Visbiome in the United States and Vivomixx in Europe.

**Key Words:** Correction; Probiotic mixture VSL#3; Intestinal barrier function; Chronic diseases; Cytokines; Therapeutic use

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Sang LX. Corrigendum to “Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases”. *World J Clin Cases* 2021; 9(20): 5752-5753

URL: https://www.wjgnet.com/2307-8960/full/v9/i20/5752.htm

DOI: https://dx.doi.org/10.12998/wjcc.v9.i20.5752

**Core Tip:** This manuscript is to further explain VSL#3 mentioned in it for probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases (*World J Clin Cases* 2020; 8: 1361-1384).

**CORRECTION**

Correction to: Cheng FS, Pan D, Chang B, Jiang M, Sang LX. Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases. *World J Clin Cases* 2020; 8: 1361-1384 PMID: 32368530 DOI: 10.12998/wjcc.v8.i8.1361.

We are the team of Min Jiang and Li-Xuan Sang from the First Affiliated Hospital, China Medical University. We published an article about probiotic mixture VSL#3 on April 26, 2020. Now we solemnly declare that the studies mentioned in this article[1] evaluated the probiotic formulation known as VSL#3 before January 31, 2016. The probiotic formulation is now commonly referred to as De Simone Formulation. In addition, the product currently known as VSL#3 is not the same as De Simone Formulation. De Simone Formulation is now available as Visbiome in the United States and Vivomixx in Europe.

**REFERENCES**

1 **Cheng FS**, Pan D, Chang B, Jiang M, Sang LX. Probiotic mixture VSL#3: An overview of basic and clinical studies in chronic diseases. *World J Clin Cases* 2020; **8**: 1361-1384 [PMID: 32368530 DOI: 10.12998/wjcc.v8.i8.1361]

**Footnotes**

**Conflict-of-interest statement:**/

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited Manuscript

**Peer-review started:** January 11, 2021

**First decision:** April 29, 2021

**Article in press:** May 24, 2021

**Specialty type:** Gastroenterology and Hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Chae Y **S-Editor:** Zhang L **L-Editor:** A **P-Editor:** Yuan YY



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**